Goldman Sachs Starts Centessa Pharmaceuticals (CNTA) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Centessa Pharmaceuticals (CNTA): Analysts Initiate With 'Buy' on 'Broad Pipeline With Significant Optionality'
June 22, 2021 8:35 AM EDTWall Street analysts have kicked off coverage of Centessa Pharmaceuticals (NASDAQ: CNTA) with a rating equivalent to Buy. So far, analysts at Jefferies, Goldman Sachs, and Morgan Stanley are all positive on the stock.
Centessa Pharmaceuticals secured $330 million in an initial public offering (IPO) in May in a bid to continue with its plan of reshaping the traditional drug development process.
The company initially intended to offer 15 million of its depositary shares in the IPO, priced between $18 and $20 per share. However, Contessa later raised the number of offered shares to 16.5 million,... More
UPDATE: Morgan Stanley Starts Centessa Pharmaceuticals (CNTA) at Overweight
June 22, 2021 12:41 AM EDT(Updated - June 22, 2021 12:41 AM EDT)
Morgan Stanley analyst Matthew Harrison initiates coverage on Centessa Pharmaceuticals (NASDAQ: CNTA) with a Overweight rating and a price target of $37.00.
The analyst comments "Centessa is a combination of 10 operating subsidiaries pursuing 16 different molecules. Each... More
UPDATE: Jefferies Starts Centessa Pharmaceuticals (CNTA) at Buy
June 22, 2021 12:24 AM EDT(Updated - June 22, 2021 7:53 AM EDT)
Jefferies analyst Eun Yang initiates coverage on Centessa Pharmaceuticals (NASDAQ: CNTA) with a Buy rating and a price target of $35.00.
The analyst commented, "As a holding company with 10 distinct subsidiaries, CNTA's broad pipeline in diverse therapeutic... More
